argenx (ARGX) Competitors

Sanofi (NASDAQ:SNY) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Does the media refer more to SNY or ARGX?

In the previous week, argenx had 18 more articles in the media than Sanofi. MarketBeat recorded 38 mentions for argenx and 20 mentions for Sanofi. Sanofi's average media sentiment score of 1.10 beat argenx's score of 0.96 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
argenx	19 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in SNY or ARGX?

argenx received 606 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 67.35% of users gave argenx an outperform vote while only 60.24% of users gave Sanofi an outperform vote.

Company	Underperform	Outperform
Sanofi	Outperform Votes 50 60.24%	Underperform Votes 33 39.76%
argenx	Outperform Votes 656 67.35%	Underperform Votes 318 32.65%

Is SNY or ARGX more profitable?

Sanofi has a net margin of 12.77% compared to argenx's net margin of -2.11%. Sanofi's return on equity of 25.61% beat argenx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	12.77%	25.61%	14.72%
argenx	-2.11%	-1.45%	-1.29%

Do institutionals & insiders have more ownership in SNY or ARGX?

14.0% of Sanofi shares are held by institutional investors. Comparatively, 60.3% of argenx shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 2.4% of argenx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Which has better earnings and valuation, SNY or ARGX?

Sanofi has higher revenue and earnings than argenx. Sanofi is trading at a lower price-to-earnings ratio than argenx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$44.29B	2.96	$6.02B	$2.49	20.82
argenx	$2.19B	16.82	-$295.05M	$12.59	48.16

Which has more volatility & risk, SNY or ARGX?

Sanofi has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.

Do analysts prefer SNY or ARGX?

Sanofi presently has a consensus price target of $62.50, indicating a potential upside of 20.56%. argenx has a consensus price target of $690.33, indicating a potential upside of 13.84%. Given Sanofi's stronger consensus rating and higher probable upside, analysts plainly believe Sanofi is more favorable than argenx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00
argenx	0 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.91

Summary

Sanofi beats argenx on 10 of the 19 factors compared between the two stocks.